Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 2
2005 2
2011 1
2012 1
2013 3
2014 2
2015 1
2017 1
2018 2
2019 1
2021 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Powell Doherty R, Marshall JL, Cabrera Puig I, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Lancet Infect Dis. 2024 Feb;24(2):e78-e79. doi: 10.1016/S1473-3099(23)00758-2. Epub 2024 Jan 3. Lancet Infect Dis. 2024. PMID: 38184003 No abstract available.
Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.
Wajja A, Nassanga B, Natukunda A, Serubanja J, Tumusiime J, Akurut H, Oduru G, Nassuuna J, Kabagenyi J, Morrison H, Scott H, Doherty RP, Marshall JL, Puig IC, Cose S, Kaleebu P, Webb EL, Satti I, McShane H, Elliott AM; TB042 Study Team. Wajja A, et al. Lancet Infect Dis. 2024 Mar;24(3):285-296. doi: 10.1016/S1473-3099(23)00501-7. Epub 2023 Nov 25. Lancet Infect Dis. 2024. PMID: 38012890 Free article. Clinical Trial.
Knowledge, Attitudes, and Practices Regarding COVID-19 among Healthcare Workers in Uganda: A Cross-Sectional Survey.
Kamacooko O, Kitonsa J, Bahemuka UM, Kibengo FM, Wajja A, Basajja V, Lumala A, Kakande A, Kafeero P, Ssemwanga E, Asaba R, Mugisha J, Pierce BF, Shattock RJ, Kaleebu P, Ruzagira E. Kamacooko O, et al. Among authors: wajja a. Int J Environ Res Public Health. 2021 Jun 30;18(13):7004. doi: 10.3390/ijerph18137004. Int J Environ Res Public Health. 2021. PMID: 34208959 Free PMC article.
Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda.
Kitonsa J, Kamacooko O, Bahemuka UM, Kibengo F, Kakande A, Wajja A, Basajja V, Lumala A, Ssemwanga E, Asaba R, Mugisha J, Pierce BF, Shattock R, Kaleebu P, Ruzagira E. Kitonsa J, et al. Among authors: wajja a. PLoS One. 2021 May 27;16(5):e0251992. doi: 10.1371/journal.pone.0251992. eCollection 2021. PLoS One. 2021. PMID: 34043693 Free PMC article.
Establishing a single-sex controlled human Schistosoma mansoni infection model for Uganda: protocol for safety and dose-finding trial.
Abaasa A, Egesa M, Driciru E, Koopman JPR, Kiyemba R, Sanya RE, Nassuuna J, Ssali A, Kimbugwe G, Wajja A, van Dam GJ, Corstjens PLAM, Cose S, Seeley J, Kamuya D, Webb EL, Yazdanbakhsh M, Kaleebu P, Siddiqui AA, Kabatereine N, Tukahebwa E, Roestenberg M, Elliott AM. Abaasa A, et al. Among authors: wajja a. Immunother Adv. 2023 Jul 20;3(1):ltad010. doi: 10.1093/immadv/ltad010. eCollection 2023. Immunother Adv. 2023. PMID: 37538934 Free PMC article.
Risk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda.
Koopman JP, Egesa M, Wajja A, Adriko M, Nassuuna J, Nkurunungi G, Driciru E, van Willigen G, Cose S, Yazdanbakhsh M, Kaleebu P, Kabatereine N, Tukahebwa E, Roestenberg M, Elliott AM. Koopman JP, et al. Among authors: wajja a. AAS Open Res. 2019 Aug 13;2:17. doi: 10.12688/aasopenres.12972.2. eCollection 2019. AAS Open Res. 2019. PMID: 31819922 Free PMC article.
Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the 'POPulation differences in VACcine responses' (POPVAC) programme.
Zirimenya L, Nkurunungi G, Nassuuna J, Natukunda A, Mutebe A, Oduru G, Kabami G, Akurut H, Onen C, Namutebi M, Serubanja J, Nakazibwe E, Akello F, Tumusiime J, Sewankambo M, Kiwanuka S, Kiwudhu F, Kizindo R, Kizza M, Wajja A, Cose S, Muwanga M, Webb E, Elliott AM; POPVAC trial team. Zirimenya L, et al. Among authors: wajja a. BMJ Open. 2021 Feb 16;11(2):e040430. doi: 10.1136/bmjopen-2020-040430. BMJ Open. 2021. PMID: 33593770 Free PMC article.
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A.
Wajja A, Namutebi M, Apule B, Oduru G, Kiwanuka S, Akello M, Nassanga B, Kabagenyi J, Mpiima J, Vermaak S, Lawrie A, Satti I, Verweij J, Cose S, Levin J, Kaleebu P, Tukahebwa E, McShane H, Elliott AM. Wajja A, et al. Wellcome Open Res. 2018 Sep 19;3:121. doi: 10.12688/wellcomeopenres.14736.1. eCollection 2018. Wellcome Open Res. 2018. PMID: 30687792 Free PMC article.
23 results